A September 2026 snapshot of Myriad Genetics: strong oncology franchises and promising new tests set against shrinking revenue, cash burn, payer friction, and the urgent question of whether the business can find a credible path back to profitability.
Myriad Genetics has something many distressed companies do not:
a real business with established products, recognized clinical franchises, and potentially valuable newer technologies.
That is what makes the investment case interesting.
The problem is that those assets are currently sitting inside a company with shrinking revenue, persistent losses, cash burn, and a business model that has not yet demonstrated a clear path back to sustainable profitability.
In other words, this is not a conventional growth thesis.
It is a recovery thesis.
And recovery theses require a higher burden of proof.
This is a snapshot of that thesis as it stands in September 2026.
It is not a recommendation to buy or sell Myriad Genetics shares.
It is an attempt to define what would have to improve, what could create upside, and what developments would signal that the thesis is breaking rather than recovering.
Company: Myriad Genetics
Ticker: MYGN
Thesis type: Distressed recovery / diagnostics / strategic optionality
Snapshot date: September 2026
Why it may be interesting:
Myriad owns established molecular-diagnostics franchises and newer oncology products with potential long-term value. At a heavily depressed valuation, stabilization of revenue and a credible path toward profitability could create substantial upside.
What the market may be underestimating:
The value of Myriad's stronger Cancer Care Continuum franchise, newer tests such as Precise MRD and Prolaris + AI, intellectual property, and potential strategic value if the company restructures or reallocates capital more effectively.
What would strengthen the thesis:
What would weaken the thesis:
Time horizon:
1–3 years, with more frequent monitoring than the other Market Vignettes
Next major checkpoints:
September 10, 2026: Wells Fargo Healthcare Conference
November 2, 2026: expected Q3 2026 earnings after market close
Current thesis status:
Under pressure, but not yet broken
Myriad Genetics develops and commercializes molecular diagnostic tests used across several areas of medicine.
Its major businesses currently fall into three broad categories:
Cancer Care Continuum, which includes hereditary cancer testing, companion diagnostics, prostate cancer testing, tumor profiling, and molecular residual disease testing.
Prenatal Health, which includes carrier screening and prenatal genetic testing.
Mental Health, centered around GeneSight, a pharmacogenomic test intended to help guide psychiatric medication decisions.
That gives Myriad something more substantial than a single speculative biotechnology asset.
It already has established clinical businesses generating hundreds of millions of dollars in annual revenue.
Myriad Genetics investor relations
The problem is not whether the company has products.
The problem is whether those products can produce enough profitable growth to support the enterprise.
The first quarter of 2026 was not especially alarming.
Revenue reached $200.4 million, up 2% year over year.
Total test volume was flat.
Cancer Care Continuum volume grew 13%, while Mental Health volume grew 7%.
Those gains were offset by a 12% decline in Prenatal Health volume.
Gross margin was 68.7%.
The company still lost money, reporting a GAAP net loss of $34.1 million and adjusted EBITDA of negative $4.5 million.
Adjusted free cash flow was approximately negative $19.9 million.
Myriad Genetics Q1 2026 results
The quarter therefore contained both halves of the thesis:
stronger oncology momentum,
but a business still burning cash.
The second quarter changed the tone materially.
Revenue fell to $190.7 million, down 11% year over year.
Total test volume declined only 1%, but average revenue per test fell 9%.
That distinction matters.
The biggest problem was not simply fewer patients being tested.
It was that Myriad was collecting less revenue for the tests it performed.
The company attributed part of that pressure to payer friction and changes in estimates of cash collections.
Myriad Genetics Q2 2026 results
That makes reimbursement one of the central variables in the thesis.
A diagnostics company can have clinically useful products and growing test volume while still struggling financially if reimbursement deteriorates.
The most encouraging area remains the Cancer Care Continuum.
Second-quarter test volume in that business grew 6% year over year.
Hereditary cancer testing volume rose 8%.
Myriad also continued expanding newer oncology products.
The company launched Prolaris + AI, combining genomics and digital pathology artificial intelligence for prostate cancer.
It expanded Precise MRD into colorectal and renal cancers.
It also submitted Precise MRD for breast cancer to MolDX for a Medicare coverage determination.
Those developments are central to the bull case.
If Myriad can build a larger oncology franchise around hereditary testing, prostate cancer, companion diagnostics, and molecular residual disease, that business could eventually become the engine that pulls the rest of the company forward.
But there is an important warning hidden inside the same quarter.
Cancer Care Continuum revenue fell 11% year over year despite volume growth.
That means volume growth alone is not enough.
The company also needs healthier reimbursement.
Prenatal Health remains the clearest source of deterioration.
Second-quarter prenatal revenue fell 16% year over year.
Volume fell 9%.
That followed a weak first quarter in which prenatal volume had already declined 12%.
The company has attributed some of the weakness to disruption associated with an order-management-system implementation and has launched new products such as FirstGene Multiple Prenatal Screen.
But from an investment perspective, explanations matter less than the trajectory.
If the prenatal business stabilizes, the overall company becomes much easier to repair.
If it continues shrinking at double-digit rates, the stronger oncology franchise has to work much harder merely to keep total revenue flat.
GeneSight has been more resilient.
Second-quarter Mental Health test volume grew 4% year over year.
Revenue, however, fell 3%, again showing the impact of weaker average revenue per test.
In the first quarter, the same business had posted 24% revenue growth.
That volatility reinforces the broader point:
Myriad's near-term problem is not simply demand.
It is the combination of demand, payer behavior, revenue recognition, and collection economics.
Second-quarter gross margin fell to 66.6%, down 460 basis points from the prior-year period.
That is significant.
Diagnostics businesses can be attractive when laboratory economics scale well.
If incremental tests generate high gross profit and fixed costs grow more slowly than revenue, operating leverage can eventually work in shareholders' favor.
But that mechanism requires relatively healthy gross margins.
A shrinking gross margin makes the path toward profitability longer.
This is why future gross-margin stabilization deserves nearly as much attention as revenue growth.
The second-quarter cash-flow picture was better than the first quarter, but still negative.
Operating cash outflow was $8.3 million.
Adjusted free cash flow was approximately negative $10.9 million.
The company ended the quarter with $115.2 million in cash and cash equivalents.
That does not imply an immediate liquidity crisis.
But it does create a clock.
A company can fund losses for a while.
It cannot burn cash indefinitely without eventually having to raise capital, sell assets, borrow money, or radically change its cost structure.
That makes one of the most important questions in the entire thesis very simple:
Can Myriad reach cash-flow sustainability before liquidity becomes a constraint?
If cash burn keeps falling, the thesis strengthens.
If it accelerates, the downside becomes much harder to ignore.
Management revised its full-year 2026 outlook after the second quarter.
The company lowered expected revenue to \$770 million to \$790 million.
It also suspended its previous full-year adjusted EBITDA guidance.
That is more serious than an ordinary quarterly miss.
When a company removes profitability guidance altogether, it signals that near-term operating visibility has deteriorated.
Myriad said the revised outlook reflected current business trends, lower Prenatal Health volume, and more conservative assumptions around average revenue per test.
For the recovery thesis, future guidance therefore becomes a major signal.
Stabilized guidance would suggest management is regaining visibility.
Another material reduction would suggest the opposite.
Myriad is not simply waiting for conditions to improve.
In Q2, management said it had begun a strategic review aimed at increasing growth, profitability, and liquidity.
The company also launched an initiative called Ascend, supported by an outside professional-services firm, to improve organizational efficiency and scalability.
Management said it was evaluating the product portfolio to determine where capital should be allocated and how shareholder value might be improved.
That introduces strategic optionality.
The company could:
That optionality matters.
But it should not become the thesis itself.
An investment case based entirely on "someone may buy something" is fragile.
The stronger thesis is still that Myriad can build a healthier operating business.
Strategic actions are a possible accelerator, not a guarantee.
The bullish interpretation is that investors may be extrapolating a very difficult operating period too far into the future.
Several pieces of the business still have value:
If revenue stabilizes while operating costs and cash burn fall, the equity could respond sharply because expectations are already extremely low.
That is the source of the upside.
There is also a straightforward reason for caution.
Unlike the other Market Vignettes, Myriad is currently dealing with:
That is a lot of moving parts that need to improve.
This does not mean the stock cannot recover.
It means the thesis should be held to a higher evidentiary standard.
A depressed share price alone is not evidence that something is cheap.
Sometimes a stock falls because the underlying economics have genuinely deteriorated.
The entire purpose of this thesis is to determine whether Myriad is temporarily impaired or structurally impaired.
The first requirement is revenue stabilization.
An 11% year-over-year decline cannot continue indefinitely.
Second, Cancer Care Continuum volume should remain healthy.
Third, reimbursement trends need to improve so that volume growth translates into revenue growth.
Fourth, gross margins should stabilize.
Fifth, operating losses and cash burn should narrow.
Sixth, newer products such as Precise MRD and Prolaris + AI need to show real commercial traction rather than simply generating promising announcements.
And finally, the strategic review needs to produce concrete actions that improve profitability or liquidity.
The thesis would become substantially weaker if:
At some point, "waiting for recovery" can become another name for avoiding a difficult conclusion.
That is why the thesis needs explicit breakers.
The first upcoming checkpoint is the Wells Fargo Healthcare Conference on September 10, 2026, at 11:00 AM Eastern.
Myriad management is scheduled to present there.
Myriad Wells Fargo Healthcare Conference announcement
The most useful things to listen for will be:
Conference presentations usually do not replace earnings reports.
But given how quickly the thesis has evolved, management's language itself may be informative.
The next major financial checkpoint is expected to be Q3 2026 earnings on November 2, after the market closes.
The questions should be direct:
For Myriad, those answers matter far more than whether quarterly EPS beats consensus by a few cents.
As of September 2026, the Myriad Genetics thesis can be summarized this way:
Myriad owns established diagnostic franchises and potentially valuable newer oncology products, but those assets are currently trapped inside a business with shrinking revenue, reimbursement pressure, persistent losses, and negative free cash flow. If revenue stabilizes, oncology growth persists, and management can materially improve profitability and liquidity, the depressed valuation could create substantial recovery upside.
That outcome is possible.
It is not yet probable enough to treat casually.
This is the lowest-conviction thesis of the four Market Vignettes so far.
That is not a reason to ignore it.
It is a reason to monitor it more carefully.
A recovery thesis earns conviction by surviving bad news and producing better evidence.
Until then, it remains a hypothesis under pressure.
And that is exactly why the thesis stays attached to a date.
Facebook
Reddit
WhatsApp
Twitter
Bình luận
Bình luận 0
Đăng nhập để tham gia cuộc trò chuyện.
Chưa có ai trả lời. Nhận xét sẽ hiển thị ở đây khi cuộc trò chuyện bắt đầu.